Merck KGaA and Serono have launched Merck Serono S.A., following the successful closing of the share purchase agreement. “With the combined innovative power of two strong companies, we have the unique opportunity to create a superb union of pharmaceutical chemistry and biotechnology,” said Elmar Schnee, new chief executive officer of Merck Serono S.A. “We want to utilize the best of both companies. A total of 28 projects in clinical development, a combined R&D budget of app...